These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30390234)

  • 21. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
    Liang CM; Kuo MT; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Wang HM; Yao CC; Tsai CE; Wang YK; Wang JW; Huang CF; Wu DC; Chuah SK;
    World J Gastroenterol; 2017 Dec; 23(47):8395-8404. PubMed ID: 29307999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
    Wu MS; Tan SC; Xiong T
    Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
    Baker R; Tsou VM; Tung J; Baker SS; Li H; Wang W; Rath N; Maguire MK; Comer GM
    Clin Pediatr (Phila); 2010 Sep; 49(9):852-65. PubMed ID: 20522615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD.
    Haddad I; Kierkus J; Tron E; Ulmer A; Hu P; Silber S; Sloan S; Leitz GJ
    J Pediatr Gastroenterol Nutr; 2014 Apr; 58(4):510-7. PubMed ID: 24164904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
    Wyrwich KW; Mody R; Larsen LM; Lee M; Harnam N; Revicki DA
    Qual Life Res; 2010 May; 19(4):551-64. PubMed ID: 20195905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):21-2. PubMed ID: 19305367
    [No Abstract]   [Full Text] [Related]  

  • 27. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
    Wittbrodt ET; Baum C; Peura DA
    Clin Exp Gastroenterol; 2009; 2():117-28. PubMed ID: 21694835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
    Lin XH; Luo JC; Ting PH; Chang TE; Huang YH; Hou MC; Lee FY
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
    Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26121347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
    Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26422095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2010 Nov; 51(5):593-8. PubMed ID: 20706150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V; Ferry G; Gunasekaran T; Huang B; Keith R; Book L
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S308-18. PubMed ID: 12607791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.
    Oldfield EC; Parekh PJ; Johnson DA
    Expert Rev Gastroenterol Hepatol; 2016 Oct; 10(10):1083-1089. PubMed ID: 27580358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
    Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
    Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
    [No Abstract]   [Full Text] [Related]  

  • 39. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study.
    Zhuang Q; Liao A; He Q; Liu C; Zheng C; Li X; Liu Y; Wang B; Liu S; Zhang Y; Lin R; Chen H; Deng M; Tang Y; He C; Dai W; Tang H; Gong L; Li L; Xu B; Yang C; Zhou B; Su D; Guo Q; Li B; Zhou Y; Wang X; Fei S; Wu H; Wei S; Peng Z; Wang J; Li Y; Wang H; Deng T; Ding S; Li F; Chen M; Xiao Y
    J Gastroenterol Hepatol; 2024 Apr; 39(4):658-666. PubMed ID: 38251791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
    Fass R; Frazier R
    Therap Adv Gastroenterol; 2017 Feb; 10(2):243-251. PubMed ID: 28203282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.